We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vanda, Probiomed in deal for schizophrenia drug Fanapt for Mexico

News

Executive Summary

Vanda Pharmaceuticals, the Rockville, Maryland-based developer of products for CNS disorders, has entered into an exclusive licence agreement with Probiomed SA, the pharmaceutical operating unit of Proquifin SA, for the commercialisation of the twice-daily, oral atypical antipsychotic Fanapt (iloperidone) in Mexico. Fanapt is Vanda's first commercial product.